Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 15 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $438,251, and 10 were calls, valued at $746,764.
What's The Price Target?
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $100.0 for Novo Nordisk during the past quarter.
Insights into Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $35.0 to $100.0 over the preceding 30 days.
Novo Nordisk Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | PUT | SWEEP | BEARISH | 06/20/25 | $21.15 | $20.15 | $21.15 | $80.00 | $296.0K | 3.8K | 10 |
| NVO | CALL | TRADE | NEUTRAL | 01/15/27 | $30.75 | $27.1 | $29.0 | $35.00 | $145.0K | 135 | 0 |
| NVO | CALL | TRADE | BEARISH | 01/16/26 | $27.7 | $27.4 | $27.4 | $35.00 | $137.0K | 45 | 50 |
| NVO | CALL | SWEEP | BEARISH | 06/20/25 | $7.85 | $7.75 | $7.8 | $55.00 | $114.6K | 330 | 155 |
| NVO | CALL | TRADE | NEUTRAL | 06/20/25 | $7.9 | $7.7 | $7.8 | $55.00 | $78.0K | 330 | 155 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
In light of the recent options history for Novo Nordisk, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of Novo Nordisk
- With a trading volume of 8,386,138, the price of NVO is up by 1.78%, reaching $59.37.
- Current RSI values indicate that the stock is may be approaching oversold.
- Next earnings report is scheduled for 15 days from now.
What The Experts Say On Novo Nordisk
In the last month, 1 experts released ratings on this stock with an average target price of $64.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from BMO Capital has revised its rating downward to Market Perform, adjusting the price target to $64.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with Benzinga Pro for real-time alerts.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
